Innovative Diagnostic Platform Inanovate has developed a groundbreaking proteomics platform that addresses a significant unmet need in early and accurate diagnosis of tick-borne diseases like Lyme disease, positioning the company as a key player in advanced medical diagnostics.

Growing Funding Momentum With a recent Series C financing of 3.1 million dollars and revenue in the range of 1 million to 10 million dollars, Inanovate shows promising growth potential and increasing investor confidence, indicating opportunities for strategic partnerships or capital infusion to scale its solutions.

Targeting Niche Market The company's focus on developing blood-based tests for cancer, autoimmune diseases, and tick-borne illnesses suggests a specialized portfolio that can be expanded through collaborations with healthcare providers and research institutions seeking innovative diagnostic solutions.

Technology Advantage Inanovate employs a sophisticated tech stack including Java, PHP, and HTTP/3, demonstrating a modern, scalable infrastructure which can appeal to potential partners interested in integrating or enhancing biotech diagnostic technologies.

Strategic Location & Operations With R&D and device production facilities in both Sioux Falls and Chapel Hill, Inanovate can leverage regional biotech ecosystems for potential co-development opportunities and benefit from proximity to major healthcare and research hubs.